We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Congress on Neuromuscular Diseases (ICNMD)
Date: July 9, 2022
Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results
Lead Author: Tracey Jason, PhD, Head of Medical Affairs at Amylyx Pharmaceuticals Canada
Published: Canadian Neurological Sciences Federation (CNSF)
Date: June 26, 2022
Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results
Lead Author: Lahar Mehta, MD, Head of Global Clinical Development at Amylyx Pharmaceuticals
Published: European Network to Cure ALS (ENCALS)
Date: June 2, 2022
Effect of Sodium Phenylbutyrate/Taurursodiol on Tracheostomy/Ventilation-Free Survival and Hospitalisation in Amyotrophic Lateral Sclerosis: Long-Term Results from the CENTAUR Trial
Lead Author: Sabrina Paganoni, MD, PhD
Published: Journal of Neurology, Neurosurgery and Psychiatry
Date: May 16, 2022
Survival Analyses from the CENTAUR Trial in Amyotrophic Lateral Sclerosis: Evaluating the Impact of Treatment Crossover on Outcomes
Lead Author: Sabrina Paganoni, MD, PhD
Published: Muscle & Nerve
Date: May 4, 2022
Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis and Alzheimer's Disease: Integrated Clinical Trial Experience
Lead Author: Steven E. Arnold, MD
Published: American Academy of Neurology (AAN)
Date: April 4, 2022
Expanded Access to Sodium Phenylbutyrate/Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Learnings From an ALS Community Partnership
Lead Author: Machelle Manuel, PhD, Head of Global Medical Affairs at Amylyx Pharmaceuticals
Published: Muscular Dystrophy Association (MDA)
Date: March 13 - 16, 2022
Global Phase 3, Randomized, Placebo-Controlled Trial of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (A35- 004 PHOENIX): Study Design Overview
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 8, 2021
Long-Term Functional Benefits and Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis
Lead Author: Sabrina Paganoni, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 7, 2021
Safety and Biological Activity of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol (PB/TURSO) for the Treatment of Alzheimer's Disease: Results from the Phase 2a PEGASUS Study
Lead Author: Steven E. Arnold, MD
Published: Clinical Trials on Alzheimer’s Disease (CTAD)
Date: November 9 - 12, 2021